• Internal Medicine
    • Medical Oncology
    • Chair, Lahey Health Cancer Institute; Director, Sophia Gordon Cancer Center; Director, Thoracic Oncology at Lahey Hospital & Medical Center; Professor of Medicine at Tufts University School of Medicine at Lahey Health Cancer Institute

    Paul J. Hesketh, M.D. is Chair of the Lahey Health Cancer Institute, Director of the Sophia Gordon Cancer Center and Director of Thoracic Oncology at Lahey Hospital & Medical Center in Burlington, Massachusetts. He is also Professor of Medicine at Tufts University School of Medicine. Dr. Hesketh has a broad interest in investigational antineoplastic therapeutics in general, with a particular focus in defining effective new treatment approaches for lung cancer and the supportive management of the patient with cancer. He serves as a member of the Core Working Group of the Lung Committee of SWOG, a National Cancer Institute sponsored nationwide clinical trials group and is the Principal Investigator for SWOG at Lahey Hospital & Medical Center. Dr. Hesketh is a past President (2006-2008) of the Multinational Association of Supportive Care in Cancer (MASCC). He has also served on a number of advisory committees for the pharmaceutical industry, American Medical Association, and the State of Massachusetts. He is a member of the antiemetic guideline committees for the American Society of Clinical Oncology (co-chair) and MASCC. He has served as a reviewer and editorial board member for a number of scientific journals and as Editor-in- Chief of the Journal of Oncology: Index & Reviews. He is an author of more than 200 scientific manuscripts, abstracts, and book chapters.

    • Hematology and Oncology
    • Executive Director at West Cancer Center

    Biography Lee S. Schwartzberg, MD, FACP is the Executive Director of the West Cancer Center in Memphis, TN. He is Professor of Medicine and Chief of the Division of Hematology/Oncology at the University of Tennessee Health Science Center. He is a scientific leader at George Clinical, a leading CRO with operations throughout the Asia-Pacific and the USA. Dr. Schwartzberg was the founding editor-in-chief of the journal Community Oncology and currently serves as the editor-in-chief of the Practice Update Oncology website. He serves on the editorial board of both the Journal of Supportive Oncology and The ASCO Post, in addition to serving as a reviewer for many prominent medical journals, including the New England Journal of Medicine and the Journal of Clinical Oncology. Dr. Schwartzberg is also a member of the Board of Directors for the National Comprehensive Cancer Network. His major research interests are new therapeutic approaches to breast cancer, targeted therapy, supportive care and patient reported outcomes. He has published more than 200 research papers during his oncology career. Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology. He maintains a practice in medical oncology focusing on breast cancer.

    • Internal Medicine
    • Medical Oncology
    • Breast Cancer
    • Febrile Neutropenia
    • CINV
    • Supportive Care
    • Investigational New Drugs in Oncology
    • Immuno-Oncology
    • Malignant Melanoma

     Bernardo Rapoport is a Medical Oncologist in private practice in Johannesburg, South Africa.  He has been in private practice as Director of the Medical Oncology Centre of Rosebank since 1993.

     After earning his medical degree in 1978 from the University of Buenos Aires in Argentina, he completed an internship at Tel Aviv University in Israel.  Dr. Rapoport then specialized in   

     Internal Medicine at the University of the Witwatersrand in Johannesburg, South Africa. He then served as a fellow in Medical Oncology at the University of Pretoria in South Africa, where he became certified as a medical oncologist and worked as a Senior Consultant and Senior Lecturer until 1993.

     Dr. Rapoport is the current President of the South African Society of Medical Oncology (SASMO), and serves on the Board of Directors of the Multinational Association of Supportive Care in Cancer (MASCC).  He is also the co-chairmen of the MASCC Antiemetic and Neutropenia, Infection and Myelosuppression study groups.

     Dr. Rapoport’s research efforts have focused on cancer supportive care, mainly febrile neutropenia and chemotherapy induced nausea and vomiting (CINV), breast cancer, melanoma ad more recently immune-oncology.  His clinical practice focuses on both solid tumours and haematological malignancies.  He has a special interest in breast and lung cancer, and immune-oncology.

     In recent years Dr. Rapoport has been involved in numerous pivotal trials of several groundbreaking therapies to treat febrile neutropenia and CINV. As frequently invited speaker, Dr Rapoport has delivered numerous lectures at local and international conferences and symposia.  He is also a reviewer for several scientific journals such as Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and Journal of Supportive Care in Cancer, and has authored and co-authored various book chapters and has published more than 80 papers in peer reviewed journals.

     Dr. Rapoport also serves as a member of the MASCC/ESMO Antiemetic Guidelines Working Group, as well as the ESMO Febrile Neutropenia and G-CSF Guidelines Committee. Dr. Rapoport is a member of the international advisory board of several multinational pharmaceutical companies.


Powered by Medstro